16
"You want to research customized vaccine technology?"
Inside the research institute's conference room, Chen Mo's words caused Shi Hongtu and the other expert members to show expressions of surprise.
Only Wu Bing was relatively calm; when she learned of Chen Mo's idea on the way here, she had also found it somewhat unbelievable.
"Yes," Chen Mo nodded.
He had carefully digested the technical data for the "Customized Vaccine System" last night and already had a rough plan in mind.
"Many medical scientists are researching customized vaccine technology, but no one can guarantee when it will succeed. We don't have that much time to research this technology right now," Shi Hongtu said.
Including Wu Bing, the other expert groups agreed with Shi Hongtu's words.
The concept of customized vaccine technology had long been proposed, and there had been some research progress, but currently in the medical field, customized vaccines were still at the stage of 'feeling for stones to cross the river'—it was somewhat inappropriate to use it in such an urgent viral incident.
They only had one month of time now; the efficacy of the improved hx3 agent could likely delay the epidemic for about a month.
After one month, the first batch of people using the improved hx3 agent would see the agent lose its effect, and a continuous stream of deaths would occur.
"This is the direction I am certain has the best chance of success," Chen Mo said.
The people in the room had strange expressions, and Shi Hongtu's eyelids even twitched.
Customized vaccine technology could be said to be one of the most difficult topics among all current research on specific drugs.
And now it had become the direction Chen Mo was most confident in? One had to say, Chen Mo's thinking was a bit unconventional.
"We don't have much time," one of the expert group members said.
"What do you mean by 'not much time'? Who can determine which type of research will take the shortest time? Do you want to research a specific drug within a month? Don't you understand how research works? Perhaps a group will announce they've found a specific drug tomorrow, or perhaps it won't be found even if all of humanity goes extinct."
Chen Mo's questions made everyone in the room quiet and a bit embarrassed.
They wanted to save patients quickly, but they had overlooked the fact that they were currently doing research.
Those of them involved in research all knew that in such matters, perhaps it would suddenly succeed tomorrow, or perhaps it might not even succeed by the time they were in their coffins; it mainly depended on whether the researchers could find that node of technological breakthrough.
If the key couldn't be found, no amount of time would be enough; if it could be found, the road ahead would be smooth.
"Customized vaccine technology is not mature, and the development speed might be slower than other agents."
A white-haired expert said, "Why don't you, Academician Chen, continue researching Hx3? The improved hx3 agent has already successfully suppressed the riedmann virus; further improvements might just be able to eliminate the virus."
This remark made the other medical experts nod one after another.
The improved hx3 agent had already achieved good results; at the very least, it worked against the riedmann virus. This was a confirmed direction.
"Hx3 is just a protease inhibitor. Its effect is limited to inhibiting the replication of viral proteins and letting the virus enter a dormant period; it cannot, by itself, deactivate the virus. Otherwise, its function wouldn't be to reduce viral activity. If it could really clear the virus, the direction of my improvements from the beginning wouldn't have been to inhibit its metabolism," Chen Mo said.
Hx3 was developed by Haixing Company using the data he provided. He knew all its functions and effects clearly. No matter how it was modified, its role was to reduce viral activity; its essence could not be changed.
"But customized vaccine technology—this technology is full of too many uncertainties."
"Regarding the research direction for a specific drug for the riedmann virus, do you have a confirmed one? Which direction is correct?" Chen Mo asked.
The breath of all the researchers in the room hitched, and they were unable to answer.
"Are you really determined to research customized vaccines?" Shi Hongtu asked.
He was the leader of the medical team, and his main task was to find a specific drug for the riedmann virus as soon as possible. Although he did not quite agree with Chen Mo researching customized vaccines, he could not influence Chen Mo's thoughts.
"Yes," Chen Mo nodded.
The scene fell into silence again. They had no good way to deal with Chen Mo's persistence.
"Let me share my thoughts."
Wu Bing spoke up, and everyone in the room looked at her.
As one of the youngest researchers in the medical team, Wu Bing's ability was no lower than anyone else's, so her words carried significant weight.
"Academician Chen forms an independent group to research customized vaccine technology, while the others research reverse transcriptase inhibitors. This way, we divide into two groups and advance in parallel. At least it provides one more option, so as to avoid hitting a dead end."
Shi Hongtu sighed. Looking at Chen Mo's stance, it was impossible for him to give up the research direction of customized antibodies; no matter how much they said, it would be useless.
Chen Mo had the right to freely choose any research direction without restrictions; this was agreed upon when Chen Mo joined the team.
Now, Chen Mo was just informing them, not asking for their opinions.
"Since Academician Chen insists, we will follow what Academician Wu said. The group led by Academician Chen will research customized vaccine technology, and the others will follow the original research plan to research reverse transcriptase inhibitors."
Shi Hongtu made the final decision.
"Who is willing to join Academician Chen's group to research customized vaccine technology together?"
Many experts in the room did not speak up. If customized vaccines were researched during normal times and came to fruition, it would be an epoch-making vaccine technology.
But now, during the period of a viral outbreak, this was not a good choice.
"It's the same as before; my team and I will join Academician Chen's group to conduct research," Wu Bing said.
Chen Mo was not surprised by this situation; it was within his expectations, and he just nodded slightly at Wu Bing.
"Alright, today's meeting is adjourned. Everyone, continue your research. If there is any progress, report it immediately for discussion. The epidemic situation outside is not optimistic right now."
Shi Hongtu's last sentence made the atmosphere heavy.
...
In a small office at the research institute, six researchers were sitting quietly.
These six people were the members of Wu Bing's team—four men and two women. They all looked very young, around thirty years old, and were the team with the lowest average age in the medical group.
They were all outstanding students of medical academicians at the Academy of Sciences or members of medical research project groups, and the lowest educational qualification among them was a medical doctorate.
At this time, Chen Mo and Wu Bing were also in the laboratory, and Chen Mo held some documents in his hand.
"I am now assigning your respective tasks. Our group's topic is customized vaccine technology. This topic is a bit difficult, and to speed up development, you must cooperate with me in the research."
Chen Mo spoke, and the few people perked up.
Although Chen Mo was not a medical school graduate, from the vfv virus onwards to the successful improvement of the hx3 agent, he had already proven his strength in agent research, which was enough for him to be a mentor to any one of them.
"Divide yourselves into two groups of three. The first group will work with Academician Wu to be responsible for isolating the virus's protective antigen genes and determining the gene sequence. The second group will work with me to build the system platform for the customized vaccine. These are your topic materials."
Chen Mo handed the materials in his hand to them.
"This is an epoch-making technology. If successful, it will have revolutionary effects on the medical field. It will allow medical scientists to quickly produce infectious disease vaccines for certain illnesses, or even mixed vaccines carrying multiple antigens."
The six people were awestruck, their hearts burning with excitement for a moment.
The country was not a disaster area and was relatively calm.
But the international medical community was not calm; almost all famous immunology doctors had been summoned to form specialized research groups.
The improved hx3 agent treated the symptoms but not the root cause.
The patients' condition was special, like severe schizophrenia patients, and it was also infectious. Countries in the disaster areas were under unprecedented pressure.
Medical facilities and epidemic prevention supplies were already in critical shortage across the board.
Protective suits, masks, and gloves were all disinfected after use and then reused, repeatedly.
This caused the infection rate among some medical personnel to rise. Some of the most severely affected countries, due to the extreme lack of medical facilities, had already gathered patients into a single isolation zone, controlled by military chemical defense units.
Now, using the hx3 agent, patients regained consciousness, making management relatively simple.
But after one month, if the backlog of patients was not cured, the agent lost its effect, and medical facilities were insufficient, then when patients lost their consciousness again, no one knew what the consequences would be.
And as time slowly passed, the medical community had not reported any good news about a breakthrough in a specific drug.
The personnel fighting on the medical front lines began to have a shadow cast over their hearts.
Because the first batch of patients who used the improved hx3 agent were about to face the consequences of the drug losing its effect.
